Edwards Lifesciences Corporatio (EW) concentration risks

The company's disclosed concentration profile reflects a product-level skew, a geographic revenue tilt, and a high-share supply-chain dependency, all of which are structurally embedded in the business model. Sales of transcatheter aortic valve replacement products represented 74% of net sales in 2025, a high share by disclosed size with a structural character — this product line is the company's core clinical franchise, and the concentration reflects deliberate focus rather than an idiosyncratic customer dependency. Any material regulatory, clinical, or competitive setback affecting that product line would directly impact the majority of revenues. The geographic exposure adds a second structural layer: 58% of net sales in 2025 were derived from customers in the United States, a high share concentrated in a single reimbursement and regulatory environment. Because U.S. payer dynamics and FDA interactions drive the bulk of commercialization economics, policy or coverage shifts in the domestic market carry a disproportionate revenue effect. On the supply side, the company purchases certain supplies from single sources — a high-share dependency by disclosed size, reflecting sole-source availability or regulatory constraints. This is the most idiosyncratic of the three exposures, as a single-source supplier disruption cannot easily be absorbed by switching to an alternate. The three exposures are interrelated: a supply disruption affecting the TAVR product line would compound the already-high product concentration, making supply continuity the most operationally acute disclosed risk.

For the engine’s reasoning on EW’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.